PuSH - Publikationsserver des Helmholtz Zentrums München

Stefan, N. ; Schick, F. ; Birkenfeld, A.L. ; Häring, H.-U. ; White, M.F.*

The role of hepatokines in NAFLD.

Cell Metab. 35, 236-252 (2023)
Postprint DOI PMC
Open Access Green
Non-alcoholic fatty liver disease (NAFLD) is not only a consequence of insulin resistance, but it is also an important cause of insulin resistance and major non-communicable diseases (NCDs). The close relationship of NAFLD with visceral obesity obscures the role of fatty liver from visceral adiposity as the main pathomechanism of insulin resistance and NCDs. To overcome this limitation, in analogy to the concept of adipokines, in 2008 we introduced the term hepatokines to describe the role of fetuin-A in metabolism. Since then, several other hepatokines were tested for their effects on metabolism. Here we address the dysregulation of hepatokines in people with NAFLD. Then, we discuss pathophysiological mechanisms of cardiometabolic diseases specifically related to NAFLD by focusing on hepatokine-related organ crosstalk. Finally, we propose how the determination of major hepatokines and adipokines can be used for pathomechanism-based clustering of insulin resistance in NAFLD and visceral obesity to better implement precision medicine in clinical practice.
Altmetric
Weitere Metriken?
[➜Einloggen]
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Review
Korrespondenzautor
Schlagwörter Hormone-binding Globulin; Fatty Liver-disease; Fetuin-a Levels; Alpha(2)-heremans-schmid Glycoprotein/fetuin-a; Incident Diabetes-mellitus; De-novo Lipogenesis; Insulin-resistance; Hepatic Steatosis; Selenoprotein P; Adipose-tissue
ISSN (print) / ISBN 1550-4131
e-ISSN 1932-7420
Zeitschrift Cell Metabolism
Quellenangaben Band: 35, Heft: 2, Seiten: 236-252 Artikelnummer: , Supplement: ,
Verlag Elsevier
Verlagsort 50 Hampshire St, Floor 5, Cambridge, Ma 02139 Usa
Nichtpatentliteratur Publikationen
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Diabetes Research and Metabolic Diseases (IDM)
Förderungen National Institutes of Health
German Federal Ministry of Education and Research (BMBF)